Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Jiao Hu, Anze Yu, Belaydi Othmane, Dongxu Qiu, Huihuang Li, Chao Li, Peihua Liu, Wenbiao Ren, Minfeng Chen, Guanghui Gong, Xi Guo, Huihui Zhang, Jinbo Chen, Xiongbing Zu
Abstract
Anti-Siglec15 immunotherapy might be suitable for BLCA treatment as Siglec15 correlates with a non-inflamed TME in BLCA. Siglec15 could also predict the molecular subtype and the response to several treatment options.
Topics & Concepts
Bladder cancerImmunotherapyImmune systemTumor microenvironmentCancerMedicineCancer immunotherapyColorectal cancerCancer researchOncologyInternal medicineImmunologyBiologyBladder and Urothelial Cancer TreatmentsFerroptosis and cancer prognosisEpigenetics and DNA Methylation